Entheon Biomedical (TSE:ENBI)
:ENBI
ENBI Stock Chart & Stats
C$0.10
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.10
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.14
Previous CloseN/A
Volume100.00
Average Volume (3M)7.96K
Market Cap
C$1.39M
Enterprise ValueC$1.06M
Total Cash (Recent Filing)C$321.83K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta4.07
Next Earnings
Apr 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding13,858,926
10 Day Avg. Volume17,012
30 Day Avg. Volume7,955
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.72
Price to Sales (P/S)0.00
P/FCF Ratio-3.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially lowers solvency and interest-cost risk, preserving flexibility to fund R&D or survive protracted development timelines without immediate interest payments. This structural advantage reduces bankruptcy risk and lengthens runway versus leveraged peers.
Improving Loss Trajectory Vs Peak YearsA materially smaller loss in 2025 versus extreme prior years suggests operational improvement or cost control, which is a durable sign management can compress burn. Sustained lower losses improve runway economics and make a path to sustainable funding or eventual profitability more feasible.
Focused Psychedelic Therapeutics IP And StrategyA concentrated R&D strategy and IP focus in psychedelic-assisted therapeutics targets large, structural mental-health and addiction markets. Specialization can create defensible niches and licensing or partnership optionality as the regulatory and clinical landscape for psychedelics matures.
Bears Say
Zero Recent RevenueAbsence of product revenue removes internal financing and market validation, forcing reliance on external funding. Over months this increases dilution risk, limits reinvestment in trials, and makes long-term commercialization and scale-up uncertain without fresh capital or partnerships.
Persistent Negative Cash Flow / Cash BurnChronic negative operating and free cash flow is a structural constraint: it erodes reserves, compels fundraising, and can force project cuts. Over a 2–6 month horizon, sustained burn undermines R&D continuity and increases execution and dilution risk absent a clear new financing plan.
Small Capital Base And Volatile EquityA modest asset base and volatile equity versus recurring losses mean limited capacity to absorb setbacks or fund trials internally. This structural fragility raises the probability of dilutive financings and weakens bargaining power with partners or acquirers over the medium term.
Entheon Biomedical News
ENBI FAQ
What was Entheon Biomedical’s price range in the past 12 months?
Entheon Biomedical lowest stock price was C$0.07 and its highest was C$0.14 in the past 12 months.
What is Entheon Biomedical’s market cap?
Entheon Biomedical’s market cap is C$1.39M.
When is Entheon Biomedical’s upcoming earnings report date?
Entheon Biomedical’s upcoming earnings report date is Apr 24, 2026 which is in 14 days.
How were Entheon Biomedical’s earnings last quarter?
Entheon Biomedical released its earnings results on Mar 27, 2026. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is Entheon Biomedical overvalued?
According to Wall Street analysts Entheon Biomedical’s price is currently Overvalued.
Does Entheon Biomedical pay dividends?
Entheon Biomedical does not currently pay dividends.
What is Entheon Biomedical’s EPS estimate?
Entheon Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entheon Biomedical have?
Entheon Biomedical has 13,858,926 shares outstanding.
What happened to Entheon Biomedical’s price movement after its last earnings report?
Entheon Biomedical reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Entheon Biomedical?
Currently, no hedge funds are holding shares in TSE:ENBI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Entheon Biomedical
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Technical Analysis
BetterLife Pharma
―
HAVN Life Sciences
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―